MCP-1 -2518 A/G gene polymorphism is associated with blood pressure in ischemic heart disease asymptomatic subjects

P Penz1, M Bucova, J Lietava

  • 11st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. pnzptr@gmail.com

Insights

Monocyte chemoattractant protein-1 (MCP-1) gene variants are linked to higher blood pressure in asymptomatic individuals with ischemic heart disease. This MCP-1 polymorphism may indicate increased cardiovascular risk before hypertension onset.

Area of Science:

  • Cardiovascular Research
  • Genetics
  • Inflammation Biology

Background:

  • Monocyte chemoattractant protein-1 (MCP-1) is a key chemokine in atherosclerosis and a risk factor for cardiovascular events.
  • Previous animal studies suggest a link between MCP-1 gene and salt-sensitive hypertension.
  • The association between MCP-1 gene polymorphism and blood pressure in asymptomatic human subjects with ischemic heart disease (IHD) remains understudied.

Purpose of the Study:

  • To investigate the association between the MCP-1 -2518 A/G single nucleotide polymorphism (SNP) and arterial blood pressure in asymptomatic subjects with IHD.
  • To evaluate inflammatory markers, cardiovascular risk factors, and absolute cardiovascular risk in relation to MCP-1 SNP.

Main Methods:

  • Genotyping of the MCP-1 -2518 A/G SNP in 66 hypertensive, asymptomatic IHD subjects.
  • Measurement of systolic and diastolic blood pressure.
  • Assessment of inflammatory markers, traditional risk factors, and the SCORE system for absolute cardiovascular risk.

Main Results:

  • Systolic and diastolic blood pressure were significantly associated with MCP-1 -2518 A/G genotype and allele frequencies.
  • Subjects with the mutant G allele or AG/GG genotypes exhibited higher blood pressure levels.
  • Individuals with AG/GG genotypes showed increased absolute cardiovascular risk and a trend towards elevated high-sensitivity C-reactive protein (hs-CRP).
  • No significant correlation was found between serum MCP-1 levels and blood pressure.

Conclusions:

  • The MCP-1 -2518 A/G polymorphism is associated with elevated blood pressure in asymptomatic IHD subjects.
  • This MCP-1 variant may contribute to increased cardiovascular risk and potentially precedes hypertension onset.
  • Larger cohort studies are required to confirm these findings and their clinical implications.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...